EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Myo-Inositol Potentiates the Inhibitory Effect of Metformin on Prolactin Levels

Robert Krysiak, Marcin Basiak, Witold Szkróbka, Bogusław Okopień

Pharmacology · 2023

DOI: 10.1159/000528542 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmacology, 2023. Verfasst von Robert Krysiak und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine and Clinical Pharmacology, Medical University of Silesia, Katowice, Poland. Hauptthemen laut MEDLINE: Metformin, Hyperprolactinemia, Insulin Resistance. Die Arbeit wurde bisher 1-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Metformin was found to reduce elevated levels of anterior pituitary hormones. Its thyrotropin-lowering effect was more pronounced in individuals receiving myo-inositol. The aim of the present study was to investigate whether the concomitant supplementation of myo-inositol determines the impact of metformin on prolactin levels.

Methods

The study population consisted of two groups of women with mild-to-moderate hyperprolactinemia. Group 1 included 24 individuals receiving myo-inositol preparations (2 g daily for at least 6 months), while 24 inositol-naïve women belonged to group 2. Both groups were matched for age, insulin sensitivity, and prolactin concentration. For the following 6 months, all women were treated with metformin (1.7 daily). Plasma glucose levels, the homeostatic model assessment of insulin resistance ratio (HOMA-IR), glycated hemoglobin, as well as plasma levels of total prolactin, monomeric prolactin, thyrotropin, free thyroid hormones, adrenocorticotropic hormone, and insulin-like growth factor-1 were measured at baseline and after 6 months of metformin treatment.

Results

Metformin reduced plasma glucose, HOMA-IR, and glycated hemoglobin in both study groups, but this effect was more pronounced in group 1 than group 2. Treatment-induced changes in total and monomeric prolactin levels were significant only in group 1. There were no differences between follow-up and baseline values of thyrotropin, free thyroxine, free tri-iodothyronine, adrenocorticotropic hormone, and insulin-like growth factor-1. Treatment-induced changes in prolactin concentration correlated with baseline prolactin levels, baseline values of HOMA-IR, and the impact of treatment on HOMA-IR.

Discussion

The obtained results suggest that myo-inositol supplementation potentiates the inhibitory effect of metformin on prolactin levels in women with hyperprolactinemia.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MetforminHyperprolactinemiaInsulin ResistanceHumansFemaleProlactinInsulin-Like Growth Factor IBlood GlucoseGlycated HemoglobinThyrotropinInositolAdrenocorticotropic Hormone

Stichwörter der Autor:innen

Insulin sensitivityMetforminMyo-inositolPituitaryProlactinhormones

Substanzen

MetforminProlactinInsulin-Like Growth Factor IBlood GlucoseGlycated HemoglobinThyrotropinInositolAdrenocorticotropic Hormone

Autor:innen und Institutionen

  • Department of Internal Medicine and Clinical Pharmacology, Medical University of Silesia, Katowice, Poland.

Zitieren

APA

Krysiak, R., Basiak, M., Szkróbka, W., & Okopień, B. (2023). Myo-Inositol Potentiates the Inhibitory Effect of Metformin on Prolactin Levels. Pharmacology. https://doi.org/10.1159/000528542

Vancouver

Krysiak R, Basiak M, Szkróbka W, Okopień B. Myo-Inositol Potentiates the Inhibitory Effect of Metformin on Prolactin Levels. Pharmacology. 2023. doi:10.1159/000528542

BibTeX
@article{Krysiak2023,
  author = {Krysiak, Robert and Basiak, Marcin and Szkróbka, Witold and Okopień, Bogusław},
  title = {Myo-Inositol Potentiates the Inhibitory Effect of Metformin on Prolactin Levels},
  journal = {Pharmacology},
  year = {2023},
  doi = {10.1159/000528542}
}
Kostenlos starten →